FDA Holds Two Death Reports Tied to Products Sold as Retatrutide
TL;DR: CBS reported on 13 Oct 2026 that the FDA holds two death reports tied to products sold as retatrutide; causation is unproven and the drug is unapproved.
What Did CBS News Report About Deaths Linked to Bootleg Retatrutide?
On 13 October 2026, CBS News reported that the US Food and Drug Administration has received reports of two deaths after people used illicit products claiming to be retatrutide, Eli Lilly’s investigational triple-agonist peptide. The reports sit in the FDA Adverse Event Reporting System (FAERS) and were obtained through a Freedom of Information Act request; CBS described them as, to its knowledge, the first public account in the United States linking retatrutide-labelled product to a death.[1][2]
According to that reporting, the first report (July 2026) was submitted by a healthcare professional and concerns a 41-year-old woman who suffered cardiac arrest after using product from an “unreliable source”; the report also notes she had been consuming kava. The second (September 2026) concerns a 49-year-old who died after severe dehydration, malnutrition and cardiac arrest, with the report alleging that a nurse sold the vials, sourced from an online peptide vendor. An attorney for that vendor told CBS there was not enough information to connect the company to the product.[1][2]
Reports, not findings. The FDA redacted identifying details, declined to say whether it had verified either report, and Lilly said neither case was tied to one of its clinical trials. Nothing in the public record establishes what the vials contained or whether they caused either death.[1]
How Should Researchers Read a FAERS Report?
FAERS is a spontaneous-reporting database. Clinicians, consumers and manufacturers can all submit reports, and the FDA does not require proof that a product caused the event. Reports therefore function as early-warning signals for pharmacovigilance teams, not as incidence data. Typical limitations include unverified product identity, unknown contents and purity, concurrent substances, incomplete clinical history and duplicate or partial entries. Our earlier guide, Retatrutide FAERS Reports Explained, covers the database in more depth.
That limitation is acute for retatrutide. Because the compound is unapproved, any product sold under its name has bypassed regulatory evaluation of identity, sterility and content. A report that says “retatrutide” records what the reporter believed the product to be, not an analytical result. This is why batch-level analytical verification, such as HPLC purity and mass confirmation, is the baseline for any laboratory work with the compound; see our guide to reading a certificate of analysis.
What Do the Latest Poison Center Numbers Show?
CBS also reported that America’s Poison Centers logged 862 retatrutide exposures in the three months ending September 2026, compared with 460 in the preceding three-month period, a near doubling.[1][3] That continues a rising trend we covered earlier in the year in Retatrutide Black-Market Sales & Poison Data 2026. As with the FAERS entries, exposure counts are unverified calls and do not establish causation, product identity or exposure level.
Separately, a medRxiv preprint analysing Reddit posts through December 2025 (13,589 users reporting current use of unapproved retatrutide) described self-reported symptoms that differed in pattern from the gastrointestinal-dominant events seen in Lilly’s trials. It is not peer-reviewed, is hypothesis-generating, and cannot estimate incidence or causation.[4]
What Is Retatrutide’s Regulatory Status Right Now?
Retatrutide is an investigational drug and has not been approved by the FDA, the MHRA or any other regulator. Third-party reporting indicates Lilly plans to submit a Biologics License Application in the first quarter of 2027, and Lilly is due to report third-quarter earnings on 29 October 2026.[5] On 8 October 2026 Lilly also filed five lawsuits against online retailers, a weight-loss clinic and a med spa over products marketed as containing retatrutide.[6] For the wider legal picture see our Lilly lawsuit summary and the FDA approval timeline.
It helps to keep three categories distinct:
1. Licensed pharmaceutical development
Lilly’s retatrutide, studied in regulated clinical trials under ethics-board and regulator oversight. This is the only context in which the compound is administered to people.
2. Unauthorised retail and online sales
Products sold under the retatrutide name with no regulatory evaluation of identity, purity or sterility; the channel to which the FAERS reports and poison-center data relate.
3. Research-use reagents
HPLC-verified material supplied strictly for in vitro laboratory work by qualified researchers, with batch documentation. Not a medicine, and never represented as fit for human or veterinary use.
What Should UK Researchers Take From This?
The reports concern US events and unapproved products, but they illustrate why provenance matters. UK laboratories sourcing reference material should require a batch-specific certificate of analysis, independent verification of identity and purity, and clear research-use-only labelling. The regulatory position is explained in Are Research Peptides Legal in the UK?, and the compound profile is at /compounds/retatrutide/.
Retatrutide reference material is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA statement.
References
- CBS News. Two deaths were reported to the FDA. Is the bootleg weight-loss drug “Reta” to blame? 13 October 2026. cbsnews.com
- Becker’s Hospital Review. 2 deaths reported to FDA after people took products claiming to be Eli Lilly’s retatrutide. October 2026. beckershospitalreview.com
- Medical Daily. Poison Center Exposures to Bootleg Retatrutide Nearly Double in Three Months as FDA Logs Two Death Reports. October 2026. medicaldaily.com
- medRxiv preprint (not peer-reviewed). Self-Reported Side Effects Among Reddit Users Taking Unapproved Retatrutide. 2026. medrxiv.org
- The Motley Fool. Eli Lilly Reports Earnings on Oct. 29. Here’s Why the Retatrutide Story Matters More Than the Quarter. 13 October 2026. fool.com
- Buchanan Ingersoll & Rooney. Eli Lilly’s Retatrutide Lawsuits: What Pharmacies, Telemedicine Companies and Online Retailers Need to Know. October 2026. bipc.com
Frequently Asked Questions
What did CBS News report about retatrutide deaths?
On 13 October 2026 CBS News reported that the FDA received two adverse event reports describing deaths after people used products claiming to be retatrutide, obtained through a Freedom of Information Act request. One report is dated July and one September 2026. Whether either product contained retatrutide, or caused the death, has not been established.
Has retatrutide caused any deaths?
That has not been established. FDA adverse event reports are unverified early-warning signals, not findings of causation. The FDA declined to say whether it had verified the two reports, and Eli Lilly stated neither case was linked to one of its clinical trials.
Is retatrutide approved anywhere?
No. As of 16 October 2026 retatrutide is an investigational drug that has not been approved by the FDA, MHRA or any other regulator. Third-party reporting says Eli Lilly plans to submit a Biologics License Application in the first quarter of 2027.
How many retatrutide poison center exposures were reported?
CBS reported that America's Poison Centers logged 862 retatrutide exposures in the three months ending September 2026, up from 460 in the preceding three months. Exposure counts are unverified reports and do not establish causation or product identity.
What is the difference between licensed retatrutide development and Velox research supply?
Lilly's retatrutide is an investigational pharmaceutical studied in regulated clinical trials. Velox Peptides supplies retatrutide solely as an HPLC-verified in vitro research reagent for qualified laboratory researchers, with batch documentation, and never as a medicine or for human or veterinary use.